Torrey Cope > Sidley Austin LLP > Washington DC, United States > Lawyer Profile
Sidley Austin LLP Offices
1501 K STREET, NW
WASHINGTON, DC 20005
DISTRICT OF COLUMBIA
United States
- Firm Profile
- Go to...
Torrey Cope
Work Department
Food, Drug and Medical Device
Position
Partner
Career
TORREY COPE advises and represents life science companies in a full range of regulatory, enforcement, litigation, and transactional matters involving FDA issues.
Torrey is an experienced, practical, and business-focused regulatory lawyer with scientific training and a passion for helping pharmaceutical, biotechnology, and medical technology companies solve their most challenging and cutting-edge regulatory problems, whether they involve clinical trials, marketing authorization, promotion, product safety, or other issues. Many of his clients are working at the forefront of life sciences innovation in fields such as immunotherapy, regenerative medicine, genetic testing/next generation sequencing (NGS), digital health, and artificial intelligence/machine learning (AI/ML).
Lawyer Rankings
United States > Healthcare > Life sciences
(Leading partners)Sidley Austin LLP advises biotech, biopharma, medical devices, and healthcare companies across the product lifecycle, with remarkable strength in regulatory and transactional matters. Its regulatory practice ensures client compliance across the marketing authorization, manufacturing, supply chain, distribution, and market access phases. On the transactional side, it handles high-value M&A and IPOs, as well as licensing agreements. The practice is led by San Francisco-based Sharon Flanagan, vastly experienced in corporate and capital markets transactions and governance matters. Washington DC’s Torrey Cope is another key member in the practice, specializing in FDA regulatory issues. Transactional lawyer Jon Olsen joined the San Diego team from Goodwin.
Lawyer Rankings
- Leading partners United States > Healthcare > Life sciences
- Life sciences United States > Healthcare
Top Tier Firm Rankings
- Investment fund formation and management > Alternative/hedge funds
- Tax > Financial products
- Industry focus > Sport
- Insurance > Insurance: non-contentious
- Tax > International tax
- Antitrust > Merger control
- Real estate > Real estate investment trusts (REITs)
- M&A/corporate and commercial > Shareholder activism
Firm Rankings
- Insurance > Advice to insurers
- Environment > Environment: litigation
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Transport > Aviation and air travel: finance
- Finance > Commercial lending
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Energy > Energy transactions: oil and gas
- Environment > Environment: transactional
- Dispute resolution > General commercial disputes
- Dispute resolution > International litigation
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Transport > Rail and road: litigation and regulation
- Dispute resolution > Securities litigation: defense
- Finance > Structured finance: securitization
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- M&A/corporate and commercial > Corporate governance
- Energy > Energy regulation: electric power
- Energy > Energy transactions: electric power
- Environment > Environment: regulatory
- Labor and employment > ERISA litigation
- Dispute resolution > International arbitration
- Intellectual property > Patents: litigation (full coverage)
- Finance > Project finance
- Real estate > Real estate
- Finance > Structured finance: derivatives and structured products
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: contentious
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending > Advice to direct lenders/private credit
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Healthcare > Life sciences
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Finance > Restructuring (including bankruptcy): corporate
- M&A/corporate and commercial > Venture capital and emerging companies
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Tax > US taxes: non-contentious
- Finance > Financial services regulation
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort